Oral contraceptive use and risk of gestational trophoblastic tumors

Journal of the National Cancer Institute

Volumn 91, Issue 7, 1999, Pages 635-640

  Palmer, Julie R ^g   Driscoll, Shirley G ^a   Rosenberg, Lynn ^h   Berkowitz, Ross S ^h   Lurain, John R ^b   Soper, John ^c   Twiggs, Leo B ^d   Gershenson, David M ^e   Kohorn, Ernest I ^f   Berman, Michael ^h   Shapiro, Samuel ^h   Rao, R Sowmya ^h  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BOSTON UNIVERSITY   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ARTICLE; CANCER RISK; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PATHOGENESIS; PRIORITY JOURNAL; TROPHOBLASTIC TUMOR;

EID: 0033531766     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.7.635     Document Type: Article

References (24)

1. Grimes DA. Epidemiology of gestational trophoblastic disease. Am J Obstet Gynecol 1984; 150:309-18.
2. Bracken MB, Brinton LA, Hayashi K. Epidemiology of hydatidiform mole and choriocarcinoma. Epidemiol Rev 1984;6:52-75.
3. Bracken MB. Incidence and aetiology of hydatidiform mole: an epidemiologic review. Br J Obstet Gynaecol 1987;94:1123-35.
4. Hayashi K, Bracken MB, Freeman DH Jr, Hellenbrand K. Hydatidiform mole in the United States (1970-1977): a statistical and theoretical analysis. Am J Epidemiol 1982;115:67-77.
5. Palmer JR. Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med 1994;39:155-62.
6. Buckley JD, Henderson BE, Morrow CP, Hammond CB, Kohorn EI, Austin DF. Case-control study of gestational choriocarcinoma. Cancer Res 1988;48:1004-10.
7. Baltazar JC. Epidemiological features of choriocarcinoma. Bull World Health Organ 1976; 54:523-32.
8. Rosenberg L, Palmer JR, Shapiro S. Gestational trophoblastic disease and use of contraceptives [letter]. Am J Obstet Gynecol 1989; 161:1087-8.
9. Brinton LA, Wu BZ, Wang W, Ershow AG, Song HZ, Li JY, et al. Gestational trophoblastic disease: a case-control study from the People's Republic of China. Am J Obstet Gynecol 1989;161:121-7.
10. Breslow NE, Day NE, Halvorsen KT, Prentice RL, Sabai C. Estimation of multiple relative risk functions in matched case-control studies. Am J Epidemiol 1978;108:299-307.
11. Berkowitz RS, Bernstein MR, Harlow BL, Rice LW, Lage JM, Goldstein DP, et al. Case-control study of risk factors for partial molar pregnancy. Am J Obstet Gynecol 1995; 173:788-94.
12. Messerli ML, Lilienfeld AM, Parmley T, Woodruff JD, Rosenshein NB. Risk factors for gestational trophoblastic neoplasia. Am J Obstet Gynecol 1985;153;294-300.
13. Berkowitz RS, Cramer DW, Bernstein MR, Cassells S, Driscoll SG, Goldstein DP. Risk factors for complete molar pregnancy from a case-control study. Am J Obstet Gynecol 1985;152:1016-20.
14. La Vecchia C, Franceschi S, Parazzini F, Fasoli M, DeCarli A, Gallus G, et al. Risk factors for gestational trophoblastic disease in Italy. Am J Epidemiol 1985;121:457-64.
15. Jacobs PA, Wilson CM, Sprenkle JA, Rosenshein NB, Migson BR. Mechanisms of origin of complete hydatidiform moles. Nature 1980; 286:714-6.
16. Smith DB, O'Reilly SM, Newlands ES. Current approaches to diagnosis and treatment of gestational trophoblastic disease. Curr Opin Obstet Gynecol 1993;5:84-91.
17. Curry SL, Schlaerth JB, Kohorn EI, Boyce JB, Gore H, Twiggs LB, et al. Hormonal contraception and trophoblastic sequelae after hydatidiform mole (a Gynecology Oncology Group Study). Am J Obstet Gynecol 1989;160: 805-11.
18. Berkowitz RS, Goldstein DP, Marean AR, Bernstein M. Oral contraceptives and post molar trophoblastic disease. Obstet Gynecol 1981; 58:474-7.
19. Ho Yuen B, Burch P. Relationship of oral contraceptives and the intrauterine contraceptive devices to the regression of concentrations of the beta subunit of human chorionic gonadotropin and invasive complications after molar pregnancy. Am J Obstet Gynecol 1983;145: 214-17.
20. Morrow P, Nakamura R, Schlaerth J, Gaddis O Jr, Eddy G. The influence of oral contraceptives on the postmolar human chorionic gonadotropin regression curve. Am J Obstet Gynecol 1985;151:906-14.
21. Deicas RE, Miller DS, Rademaker AW, Lurain JR. The role of contraception in the development of postmolar gestational trophoblastic tumor. Obstet Gynecol 1991;78: 221-6.
22. Dawson DA. Trends in use of oral contraceptives - data from the 1987 National Health Interview Survey. Fam Plann Perspect 1990;22: 169-72.
23. van Leeuwen FE, van Duijn CM, Camps MH, Kempers BA, Mentjens MF, Mulder HB, et al. Agreement between oral contraceptive users and prescribers: implications for case-control studies. Contraception 1992;45: 399-408.
24. Nischan P, Ebeling K, Thomas DB, Hirsch U. Comparison of recalled and validated oral contraceptive histories. Am J Epidemiol 1993;138: 697-703.